Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02091141
Other study ID # ML28897
Secondary ID PRO 02
Status Completed
Phase Phase 2
First received
Last updated
Start date April 14, 2014
Est. completion date May 24, 2023

Study information

Verified date February 2024
Source Genentech, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.


Recruitment information / eligibility

Status Completed
Enrollment 673
Est. completion date May 24, 2023
Est. primary completion date May 24, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility General Inclusion Criteria: - Life expectancy greater than or equal to (=) 12 weeks - Histologically documented metastatic cancer (solid tumors, not including hematologic malignancies) - Participants who have received standard first-line therapy for metastatic cancer (except for the tumors for which no first-line therapy exists) and in whom a trial of targeted therapy is considered the best available treatment option. Eligible participants should not have available therapies that will convey clinical benefit and/or are not suitable options per the treating physician's judgment - No previous treatment with the specific assigned study drug or any other drug sharing the same target - Measurable disease by RECIST v1.1 - Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 (For patients enrolling in the atezolizumab arm, ECOG score must be documented within 7 days prior to first treatment and confirmation of ECOG PS must be entered into the interactive web response system [IWRS] prior to initiation of treatment) - Adequate hematologic, renal, and liver function as defined by the protocol - If applicable, use of contraception methods or abstinence as defined by the protocol Study-Drug Specific Inclusion Criteria: Trastuzumab plus Pertuzumab - Molecular testing results from clinical laboratory improvement amendments (CLIA)-certified laboratories (using tissue and/or blood) demonstrating HER2 overexpression or amplification. Participants must have one of the following tumor types: biliary cancer, salivary cancer, or bladder cancer a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment) - Left ventricular ejection fraction (LVEF) greater than (>) 50 percent (%) or above the lower limit of the institutional normal range, whichever is lower - Availability of an archival or new pre-treatment tissue sample is required if molecular testing was not performed by Foundation Medicine. Any available tumor tissue sample can be submitted. The tissue sample must be submitted within 4 weeks after enrollment Erlotinib - Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating epidermal growth factor receptor (EGFR)-activating mutations Vemurafenib plus Cobimetinib - Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating BRAF V600 mutations a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment) Vismodegib - Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating hedgehog pathway relevant mutation (activating mutation of smoothened [SMO] or loss-of-function mutation of protein patched homolog-1 [PTCH-1]) a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment) - All non-hematological adverse events related to any prior chemotherapy, surgery, or radiotherapy must have resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade less than or equal to (=) 2 prior to starting therapy Alectinib - Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating anaplastic lymphoma kinase (ALK) gene rearrangements, ALK mutations, ALK copy number gain or (for melanoma only) increased ALK expression or presence of ALK-alternative transcription initiation transcript (ALKATI) a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment) Atezolizumab - Molecular testing results from CLIA-certified laboratories (using tissue) demonstrating elevated tissue tumor mutational burden (tTMB =10 mutations/ Megabase [Mb]) - For patients where molecular testing was not performed using Foundation Medicine, submission of an archival or new pretreatment tissue sample is mandatory. For patients where molecular testing was performed using Foundation Medicine, submission of an archival or new pretreatment tissue sample is required, if available. The tissue sample must be submitted within 4 weeks after enrollment General Exclusion Criteria: - Participants with hematologic malignancies - Concurrent administration of any other anti-cancer therapy (except male participants with prostate cancer receiving androgen blockade): Bisphosphonates and denosumab are allowed; Most recent anti-cancer therapy =28 days and have not recovered from the side effects, excluding alopecia; Radiation therapy within =14 days - Active or untreated brain metastases - History of carcinomatous meningitis - Uncontrolled concurrent malignancy (early stage is allowed if not requiring active therapy or intervention) - Pregnant or breastfeeding women, or intending to become pregnant during the study - Any significant cardiovascular events within 6 months prior to study entry - Pulmonary embolism within 30 days prior to study entry - History or presence of clinically significant ventricular or atrial dysrhythmia >Grade 2 per NCI CTCAE v4.0 - Any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results - Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol Study-Drug Specific Exclusion Criteria: Trastuzumab plus Pertuzumab - Previous treatment with any HER2-targeted therapy Erlotinib - Non-small cell lung cancer (NSCLC) or pancreatic cancer identified by exon 19 deletions or exon 21 L858R substitution mutations - EGFR amplifications in the absence of EGFR-activating mutations - Cancers with exon 20 mutations - Previous treatment with erlotinib or any other EGFR inhibitor - Inability to swallow pills - Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of erlotinib Vemurafenib plus Cobimetinib - Malignant melanoma, papillary thyroid cancer, colorectal cancer, or hematologic malignancy including multiple myeloma - LVEF below institutional lower level of normal (LLN) or below 50%, whichever is lower - History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment, retinal vein occlusion (RVO), or neovascular macular degeneration - Presence of any of the following conditions, which are risk factors for RVO: Uncontrolled glaucoma with intraocular pressure >21 millimetres of mercury (mm Hg); Serum cholesterol =Grade 2; Hypertriglyceridemia =Grade 2; Hyperglycemia (fasting) =Grade 2; Grade =2 uncontrolled hypertension (participants with a history of hypertension controlled with anti-hypertensive medication to Grade </=1 are eligible) - Prior or concurrent malignancy with known RAS mutation - Previous treatment with vemurafenib or any other BRAF inhibitor (prior sorafenib is allowed) - Previous treatment with cobimetinib or any other mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor - Prior treatment with a RAF inhibitor - Inability to swallow pills - Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of vemurafenib - History of congenital long QT syndrome or mean (average of triplicate measurements) corrected QT (QTc) measured using Fridericia's method =450 millisecond (ms) at baseline or uncorrectable abnormalities in serum electrolytes (sodium, potassium, calcium, magnesium, phosphorus) Vismodegib - Basal cell carcinoma of the skin, medulloblastoma, small-cell lung cancer, or hematologic malignancies - Previous treatment with vismodegib or any other hedgehog pathway inhibitor - Inability to swallow pills - Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of vismodegib Alectinib - ALK-positive NSCLC, neuroblastoma, and childhood tumors - Previous treatment with alectinib or any other ALK inhibitor - Participants with symptomatic bradycardia - Administration of strong/potent cytochrome P3A4 (CYP3A4) inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib - Inability to swallow pills - Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of alectinib Atezolizumab - History of leptomeningeal disease - Uncontrolled tumor pain - Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment - Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters are allowed - Uncontrolled or symptomatic hypercalcemia - Previous treatment with atezolizumab or another programmed death-1 (PD-1)/PD-L1 inhibitor - History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins - Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells - Known allergy or hypersensitivity to any component of the atezolizumab formulation - Active or history of autoimmune disease or immune deficiency - Prior allogeneic stem cell or solid organ transplantation - History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan - Positive human immunodeficiency virus (HIV) test, active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection or active tuberculosis - Severe infection within 4 weeks prior to initiation of study treatment - Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment - Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina - Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study - Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study or within 5 months after the final dose of atezolizumab - History of other malignancy within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer - Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the participant at high risk from treatment complications - Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies - Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug (whichever is longer) prior to randomization - Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study

Study Design


Intervention

Drug:
Trastuzumab
Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Pertuzumab
Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Erlotinib
Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Vemurafenib
Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Cobimetinib
Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Vismodegib
Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Alectinib
Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Atezolizumab
Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Locations

Country Name City State
United States University of New Mexico Albuquerque New Mexico
United States University of New Mexico Comprehensive Cancer Center Albuquerque New Mexico
United States University of New Mexico Comprehensive Cancer Center - Albuquerque Cedar Street; Drug Shipment Albuquerque New Mexico
United States University of New Mexico Comprehensive Cancer Center - Albuquerque Lang NE; Drug Shipment Albuquerque New Mexico
United States University Cancer & Blood Center, LLC; Research Athens Georgia
United States University of Colorado Aurora Colorado
United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland
United States Univ No Carolina School of Med; Physicians Office Bldg Chapel Hill North Carolina
United States SCRI Tennessee Oncology Chattanooga Chattanooga Tennessee
United States Northwestern University; Robert H. Lurie Comp Can Ctr; Northwestern Medicine Development Inst Chicago Illinois
United States University Of Chicago Medical Center; Section Of Hematology/Oncology Chicago Illinois
United States Oncology Hematology Care Inc Cincinnati Ohio
United States Cleveland Clinic Cleveland Ohio
United States University Hospitals of Cleveland Cleveland Ohio
United States Science 37, Inc Culver City California
United States City of Hope Comprehensive Cancer Center Duarte California
United States Duke University Medical Center Durham North Carolina
United States Sanford Roger Maris Cancer Center Fargo North Dakota
United States San Juan Oncology Associates Farmington New Mexico
United States SCRI Florida Cancer Specialists South Fort Myers Florida
United States The Center for Cancer and Blood Disorders - Fort Worth Fort Worth Texas
United States Northeast Georgia Medical Center; Oncology Research Dept-5C Gainesville Georgia
United States West Clinic Germantown Tennessee
United States Western Regional Medical Center at Cancer Treatment Centers of America Goodyear Arizona
United States Memorial Sloan Kettering Cancer Center at Westchester Harrison New York
United States MD Anderson Houston Texas
United States Mayo Clinic Jacksonville Florida
United States Research Medical Center - Antibiotic Research Associates, Inc. Kansas City Missouri
United States Tennessee Cancer Specialists Knoxville Tennessee
United States Moores UCSD Cancer Center; Dept Clinical Trials Office La Jolla California
United States University of Wisconsin Madison Wisconsin
United States Memorial Sloan Kettering - Monmouth Middletown New Jersey
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Tennessee Onc., PLLC - SCRI Nashville Tennessee
United States Vanderbilt Ingram Cancer Clinic Nashville Tennessee
United States Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion New York New York
United States Memorial Sloan Kettering Cancer Center New York New York
United States Weill Cornell Univ Medical Ctr; Breast Cancer Center New York New York
United States Southeastern Regional Medical Center, Inc. Newnan Georgia
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States Florida Hospital Cancer Inst; Memorial System Onc Clin Rsch Orlando Florida
United States Abramson Cancer Center Philadelphia Pennsylvania
United States Eastern Regional Medical Ctr Philadelphia Pennsylvania
United States Thomas Jefferson University Hospital Philadelphia Pennsylvania
United States Mayo Clinic Arizona Phoenix Arizona
United States UPMC - Hillman Cancer Center Pittsburgh Pennsylvania
United States Providence Portland Medical Center Portland Oregon
United States Eisenhower Medical Center Rancho Mirage California
United States Virginia Cancer Institute Richmond Virginia
United States Mayo Foundation Rochester Minnesota
United States Florida Cancer Specialist, North Region Saint Petersburg Florida
United States Sanford Cancer Cnt Onco Clinic Sioux Falls South Dakota
United States Highlands Oncology Group Springdale Arkansas
United States Stanford Comprehensive Cancer Center Stanford California
United States Northwest Medical Specialties Tacoma Washington
United States Kaiser Permanente - Vallejo Vallejo California
United States Florida Cancer Specialists, Research Department West Palm Beach Florida
United States Abington Mem Hosp-Abington; Rose. Can Ctr,Gyn Onc Ins Willow Grove Pennsylvania
United States Wake Forest Univ Health Svcs; Internal Medicine Winston-Salem North Carolina
United States Midwestern Regional Med Center Zion Illinois

Sponsors (1)

Lead Sponsor Collaborator
Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator Tumor response will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for all arms. From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 9 years)
Primary Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) =16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC) Tumor response will be assessed using RECIST version 1.1. From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 9 years)
Secondary Percentage of Participants With Disease Control Tumor response will be assessed using RECIST version 1.1 for all arms. From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 9 years)
Secondary Progression-Free Survival (PFS) Tumor response will be assessed using RECIST version 1.1 for all arms. From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 9 years)
Secondary Percentage of Participants who are Alive at Year 1 1 year
Secondary Duration of Response Tumor response will be assessed using RECIST version 1.1 for all arms. From the date of first documented response (complete response [CR] or partial response [PR]) to the time of disease progression or death from any cause, whichever occurs first (up to approximately 9 years)
Secondary Percentage of Atezolizumab-Treated Participants with tTMB =10 Mutations/Mb and <16 Mutations/Mb With Overall Response, as Assessed by the Investigator Tumor response will be assessed using RECIST version 1.1. From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 9 years)
Secondary Percentage of Atezolizumab-Treated Participants with Blood Tumor Mutational Burden (bTMB) =16 Mutations With Overall Response, as Assessed by the IRC Tumor response will be assessed using RECIST version 1.1. From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 9 years)
Secondary Percentage of Participants With Adverse Events From first study treatment administration to 30 days (45 days for vismodegib, 90 days for atezolizumab) after the last dose (up to approximately 9 years)
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Not yet recruiting NCT02806557 - Profiling Neutrophil Counts in Patients on Chemotherapy N/A